The U.S. FDA cleared Medtronic’s Hugo robotic‑assisted surgery (RAS) system and CMR Surgical’s Versius Plus system for the U.S. market, introducing new commercial alternatives to Intuitive Surgical’s da Vinci platform. The approvals expand hospital purchasing options for soft‑tissue robotic procedures and support growing procedure volumes for minimally invasive surgery. Both entrants will compete on system cost, workflow integration, and service models; hospital systems evaluating robotics will weigh total cost of ownership alongside clinical training and capital deployment. Intuitive remains the market leader, but the FDA nods signal increasing regulatory acceptance of competing robotic architectures. Device vendors, health systems and investors should track initial adoption metrics, reimbursement dynamics, and surgeon training outcomes to assess whether the new systems can meaningfully dent incumbent market share.